Tharimmune (NASDAQ:THAR) Stock Price Down 7.2% – Time to Sell?

Tharimmune, Inc. (NASDAQ:THAR)’s stock price traded down 7.2% on Thursday . The company traded as low as $2.32 and last traded at $2.32. 1,113,844 shares were traded during mid-day trading, a decline of 25% from the average daily volume of 1,476,877 shares. The stock had previously closed at $2.50.

Tharimmune Price Performance

The stock’s 50 day simple moving average is $3.02 and its two-hundred day simple moving average is $3.48. The stock has a market cap of $89.80 million, a price-to-earnings ratio of -0.60 and a beta of 1.43.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in shares of Tharimmune in the 2nd quarter valued at about $25,000. Essex LLC acquired a new position in shares of Tharimmune during the fourth quarter valued at about $31,000. Drucker Wealth 3.0 LLC raised its stake in shares of Tharimmune by 150.0% in the fourth quarter. Drucker Wealth 3.0 LLC now owns 25,337 shares of the company’s stock worth $77,000 after purchasing an additional 15,202 shares during the last quarter. Franklin Resources Inc. purchased a new position in Tharimmune during the 2nd quarter worth $88,000. Finally, State Street Corp grew its position in Tharimmune by 109.0% in the 4th quarter. State Street Corp now owns 36,621 shares of the company’s stock worth $111,000 after purchasing an additional 19,100 shares in the last quarter. Institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.